SOURCE: Atossa Genetics, Inc.

Atossa Genetics, Inc.

August 21, 2013 08:30 ET

Atossa Genetics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference

SEATTLE, WA--(Marketwired - Aug 21, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that Dr. Steven C. Quay, Chairman, CEO and President, and Mr. Kyle Guse, Chief Financial Officer & General Counsel, will present the Company's products, services and business strategy at the 15th Annual Rodman & Renshaw Global Investment Conference on Monday, September 9, 2013, at the Millennium Broadway Hotel in New York City.

The Company's presentation is scheduled to begin at 4:30 p.m. EDT and will be available via a live webcast. To access the webcast, please go to or

About Atossa Genetics

Atossa Genetics, Inc., based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc. ("NRLBH"), patented laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information on Atossa, please visit For additional information on the ForeCYTE test and the National Reference Laboratory for Breast Health, please visit

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with planned and ongoing product launches, expected levels of future expenditures, actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q, each as amended and supplemented from time to time.

Contact Information

  • Contact:
    Atossa Genetics, Inc.
    Kyle Guse
    CFO and General Counsel
    (O) 800-351-3902
    Email Contact

    MBS Value Partners
    Matthew D. Haines (Investors)
    Managing Director
    (O) 212-710-9686
    Email Contact

    JQA Partners
    Jules Abraham (Media)
    (O) 917-885-7378
    Email Contact